You are here

Hodgkin Lenfoma İzleminde Pozitron Emisyon Tomografisi (Pet) Kullanımının Rolü

The Role of Positron Emission Tomography (Pet) For Hodgkin Lymphoma Follow-Up

Journal Name:

Publication Year:

Abstract (2. Language): 
The aim of this study is To evaluate the role of Positron Emission Tomography (PET) for the detection of treatment response and recurrent disease in patients with Hodgkin lymphoma (HL), who had been treated with radiotherapy (RT). A total of 15 patients with the diagnosis of HL, who had been treated and followed by PET scan in the Radiation Oncology Department of Uludag University between April 2003 and August 2005, were included in the study. The median age was 26 (10-52) years. Three patients were women and 12 patients were male. One patient had stage I disease, 5 patients were stage II disease, 9 patients had stage III disease. Five patients had B symptoms. The patients had undergone a median of 6 (3-6) cycles of chemotherapy (CT) before RT. RT areas were as follows; mantle in 11 patients, mantle+paraaortic in 2 patients, involved field in one patient, and subtotal nodal irradiation in one patient. The median total RT dose was 39,6 (30,6-45) Gy. PET scan was performed on a median 2 months (1-5) after RT. Conventional radiological examinations were also used for follow-up. The median follow-up period of the patients was 36 months (21-49). Mediastinal hyperactivity was found in two patients by PET scan that was performed after the completion of RT and CT. However other 13 patients exhibited residual lymph nodes by conventional radiological examinations, PET scan showed normal findings. Mediastinoscopy and lymph node sampling were carried out in two patients, who showed mediastinal hyperactivity by PET scan. One of these patients had disease recurrence, and the other had xanthogranulomatous reaction only. It is concluded that PET is a valuable scanning method for staging, response evaluation and follow-up of patients with HL. It has high sensitivity and specifity for the evaluation of lymph node involvement.
Abstract (Original Language): 
Bu çalışmanın amacı Hodgkin Lenfoma (HL) tanısıyla radyoterapi (RT) uygulanan hastalarda Fluorodeoksiglukoz-Pozitron Emisyon Tomografisi’nin (PET) tedavi cevabı ve nüks hastalığı belirlemedeki rolünü saptamaktır. Çalışmaya Nisan 2003-Ağustos 2005 tarihleri arasında Uludağ Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalı’nda HL nedeniyle tedavi edilen ve takiplerinde PET kullanılan 15 hasta dahil edilmiştir. Hastaların ortanca yaşı 26 (10-52) yıldı. Üç hasta kadın, 12 hasta ise erkekti. Bir hasta evre I, 5 hasta evre II, 9 hasta evre III’dü. Beş hastada B semptomları bulunuyordu. Hastalara RT öncesi ortalama 6 (3-6) kür kemoterapi (KT) uygulanmıştı. RT alanları; 11 hastada mantle, 2 hastada mantle+paraaortik, 1 hastada tutulmuş alan, 1 hastada da subtotal nodal ışınlamadır. Ortanca toplam RT dozu 39,6 (30,6-45) Gy’dir. Hastalara RT sonrası ortalama 2. ayda (1-5) PET çekimi yapıldı. Takipte diğer konvansiyonel radyolojik görüntüleme yöntemleri de kullanıldı. Hastaların ortanca takip süresi 36 (21-49) aydır. KT ve RT sonrası iki hastanın PET tetkikinde mediastinal hiperaktivite saptandı. Diğer 13 hastanın konvansiyonel radyolojik görüntülemelerinde rezidü lenf nodu mevcut iken, PET incelemeleri normal sonuçlandı. PET’de mediastinal hiperaktivite saptanan iki hastaya mediastinoskopi ve lenf nodu örneklemesi yapıldı. Bir hastada hastalık yinelemesi, diğer hastada ise ksanto-granülomatöz reaksiyon saptandı. PET’in, HL hastalarında evreleme, tedavi cevabını değerlendirme ve takipte kullanılan değerli bir görüntüleme yöntemi olduğu ve lenf nodu tutulumunun değerlendirilmesinde duyarlılığının ve özgüllüğünün yüksek olduğu sonucuna varıldı.
51-54

REFERENCES

References: 

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer
istatistics, 1994. CA Cancer J Clin 1994;44:7-26.
2. O’Doherty MJ, Marsden PK. Being equipped for clinical PET.
Lancet 2000;356:1700-3.
3. Kostakoglu L, Goldsmith SJ. Fluorine-18-fluorodeoxyglucose
- positron emission tomography in the staging of and follow
up of lymphoma: is it time to shift a gear. Eur J Nucl Med
2000;27:1564-78.
4. Mijnhout GS, Hooft L, van Tulder MW, Dewillw WL, Teule
GJ, Hoekstra OS. How to perform a comprehensive search for
FDG-PET literature. Eur J Nucl Med 2000;27:91-7.
5. Acland K.M. Healy C, Calonje E, at al. Calonje E, et al.
Comparison of PET scanning and sentinel node biopsy in the
detection of micrometastases of clinical stage I malignant
melanoma. J Clin Oncol 2001;19:2674-8.
6. Weihradch MR, Re D, Bischoff S, et al. Whole-body positron
emission tomography using 18F-fluorodeoxyglucose for initial
staging of patients with Hodgkin’s disease. Ann Hematol
2002; 81:20-5.
7. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-
[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hogkin’s disease. Ann
Oncol 1998;9:1117-22.
8. Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of
whole body FDG-PET on the staging and therapeutic decision
making for malignant lymphoma. Ann Nucl Med
2002;16:337-45.
9. Dang CV, Semenza GI. Oncogenic alterations of metabolism.
Trends Biochem Sci 1999;24:68-72.
10. Smith TA. FDG uptake, tumour characteristics, and response
to therapy: a review. Nucl Med Commun 1998;19:97-105.
11. Okada J, Yoshikawa K, Itami M, et al. Positron emission
tomography using fluorine-18-deoxyglucose in malignant
lymphoma: a comparison with proliferative activity. J Nucl
Med 1992;33:325-9.
12. Zasadny KR, Wahl RL. Standardized uptake values of normal
tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose:
variations with body weight and a method for correction. Radiology 1993;189:847-50.
13. Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E,
Nitzsche EU. Increased metabolic activity in the thymus gland
studied with (18) F-FDG PET: Age dependency and frequency after chemotherapy. J Nucl Med 2001;42:591-5.
14. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on
whole body imaging. Semin Nucl Med 1998; 28:352-8.
15. Paul R. Comparison of fluorine-18-2FDG and gallium-67
citrate imaging for detection of lymphoma. J Nucl Med 1987;
28:288-92.
16. Bangerter M, Moog F, Buchmann I, et al. Whole body 2-[18F]
fluoro-2-deoxy-D-glucose positron emission tomography
(FDG-PET) for accurate staging of Hodgkin’s disease. Ann
Oncol 1998;9:1117-22.
17. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R,
Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.
Nucl Med Commun 1998;19:1055-63.
18. Hueitenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole
body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001;91:302-10.
19. Partridge S, Timothy A, O’Doherty MJ, Hain S, Rankin S,
Mikaeel G. Fluorodeoxyglucose positron emission tomograpy
and the pretreatment staging of Hodgkin disease. Ann Oncol
2000;11:1273-9.
20. Weidmann E, Baican B, Hertel A, et al. Positron emission
tomography (PET) for staging and evaluation of response to
treatment in patients with Hodgkin’s disease. Leukemia Lymphoma 1999;34:545-51.
21. Partridge S, Timoth A, O’Doherty MJ, et al. 2-Fluorine-18-
fluoro-2-deoxyglucose positron emission tomography in the
pretreament staging of Hodgkin’s disease: influence on patient
management in a single institution. Ann Oncol 2000;11:1273-
9.
22. Moog F, Bangerter M, Diederichs CG.,et al. Lymphoma. Role
of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG)
PET in nodal staging. Radiol 1997;203:795-800.
23. Bangerter M, Moog F, Griesshammer M, et al. Usefulness of
FDG-PET diagnosing primary lymphoma of the liver. Int J
Hematol 1997;66:517-20.
24. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of
lymphoma with PET with 2-[F-18]-Fluoro-2-deoxy-Dglucose: correlation with CT. Radiology 1994;192:111-6.
25. Jerusalem G. Warland V, Majjar F, et al. Whole-body 18FFDG-PET for the evaluation of patient with Hodgkin’s disease
and non-Hodgkin’s lymphoma. Nucl Med Commun
1999;20:13-20.
26. Jerusalen G, Beguin Y, Fassotte MF, et al. Whole body positron emission tomography using
18
F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 2001;86:266-73.
27. Canellos GP. Residual mass in lymphoma may not be residual
disease. J Clin Oncol 1988;6:931-3.
28. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after firstline treatment distinguish Hodgkin's disease patients who need
additional therapy from others in whom additional therapy
would mean avoidable toxicity? Br J Haematol 2001;115:272-
8.
29. Mikhael NG, Timothy AR, O’Doherty MJ, Hain SF, Maisey
MN. l8-FDG-PET as a prognostic indicator in the treatment of
aggressive non-Hodgkin’s lymphoma. Leukemia Lymphoma
2000;39:543-53.

Thank you for copying data from http://www.arastirmax.com